Noninvasive Physical Plasma as Innovative and Tissue-Preserving Therapy for Women Positive for Cervical Intraepithelial Neoplasia.
Raman imaging
cervical intraepithelial neoplasia (CIN)
clinical plasma application
low- and high-grade squamous intraepithelial lesions (LSILs and HSILs)
physical atmospheric pressure plasma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Apr 2022
12 Apr 2022
Historique:
received:
14
03
2022
revised:
04
04
2022
accepted:
07
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
(1) Background: Cervical intraepithelial neoplasia (CIN) of long-term persistence or associated with individual treatment indications often requires highly invasive treatments. These are associated with risks of bleeding, infertility, and pregnancy complications. For low- and middle-income countries (LMICs), standard treatment procedures are difficult to implement and manage. We characterized the application of the highly energized gas "noninvasive physical plasma" (NIPP) for tissue devitalization and the treatment of CIN. (2) Methods: We report the establishment of a promising tissue devitalization procedure by NIPP application. The procedure was characterized at the in vitro, ex vivo and in vivo levels. We performed the first prospective, single-armed phase-IIb trial in 20 CIN1/2 patients (NCT03218436). (3) Results: NIPP-treated cervical cancer cells used as dysplastic in vitro model exhibited significant cell growth retardation due to DNA damage, cell cycle arrest and apoptosis. Ex vivo and in vivo tissue assessments showed a highly noninvasive and tissue-preserving treatment procedure which induces transmucosal tissue devitalization. Twenty participants were treated with NIPP and attended a 24-week follow-up. Treatment success was achieved in 19 (95%) participants without postinterventional complications other than mild to moderate discomfort during application. (4) Conclusions: The results from this study preliminarily suggest that NIPP could be used for an effective and tissue-preserving treatment for CIN without the disadvantages of standard treatments. However, randomized controlled trials must confirm the efficacy and noninferiority of NIPP compared to standard treatments.
Identifiants
pubmed: 35454839
pii: cancers14081933
doi: 10.3390/cancers14081933
pmc: PMC9027888
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Faculty of Medicine of the Eberhard Karls University Tübingen
ID : 2432-1-0
Organisme : Faculty of Medicine of the Eberhard Karls University Tübingen
ID : IZKF 2018-1-06
Organisme : Deutsche Forschungsgemeinschaft
ID : INST 2388/34-1
Organisme : Deutsche Forschungsgemeinschaft
ID : INST 2388/64-1
Organisme : Deutsche Forschungsgemeinschaft
ID : GRK 2543/1
Références
Faraday Discuss. 2004;126:141-57; discussion 169-83
pubmed: 14992404
Br J Cancer. 2004 Aug 31;91(5):942-53
pubmed: 15292939
Cancers (Basel). 2020 Jan 22;12(2):
pubmed: 31979067
Reprod Biol Endocrinol. 2009 Dec 07;7:144
pubmed: 19968870
Nucleic Acids Res. 2003 Aug 15;31(16):4779-90
pubmed: 12907719
ACS Chem Neurosci. 2018 Dec 19;9(12):3038-3048
pubmed: 30024146
Oncotarget. 2017 Feb 28;8(9):15977-15995
pubmed: 27845910
Sci Rep. 2019 May 7;9(1):7014
pubmed: 31065074
Int J Gynecol Pathol. 1993 Apr;12(2):186-92
pubmed: 8463044
Biopolymers. 1975 Feb;14(2):379-91
pubmed: 1174668
Ther Adv Med Oncol. 2018 Jul 20;10:1758835918786475
pubmed: 30046358
J Cancer Res Ther. 2016 Apr-Jun;12(2):938-44
pubmed: 27461678
Anticancer Res. 2017 Dec;37(12):6739-6744
pubmed: 29187451
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Int J Mol Sci. 2020 Apr 22;21(8):
pubmed: 32331263
ACS Appl Mater Interfaces. 2019 Jun 5;11(22):19841-19853
pubmed: 31071258
PLoS One. 2016 Sep 01;11(9):e0160667
pubmed: 27584003
Biomedicines. 2021 Feb 10;9(2):
pubmed: 33578986
PLoS One. 2015 Jul 01;10(7):e0130350
pubmed: 26132846
Oncogene. 2001 May 28;20(24):3021-7
pubmed: 11420717
In Vivo. 2015 Sep-Oct;29(5):611-6
pubmed: 26359422
Lancet Oncol. 2020 Jan;21(1):175-184
pubmed: 31734069
Spectrochim Acta A Mol Biomol Spectrosc. 2005 May;61(7):1529-35
pubmed: 15820887
J Low Genit Tract Dis. 2020 Apr;24(2):102-131
pubmed: 32243307
Biophys J. 1991 Nov;60(5):1046-56
pubmed: 1760504
Geburtshilfe Frauenheilkd. 2019 Feb;79(2):160-176
pubmed: 30792546
ACS Appl Mater Interfaces. 2019 Nov 20;11(46):42885-42895
pubmed: 31657892
PLoS One. 2020 May 6;15(5):e0232724
pubmed: 32374749
Cancers (Basel). 2019 Jul 22;11(7):
pubmed: 31336648
Biophys J. 2018 Jun 5;114(11):2498-2506
pubmed: 29874601
Cochrane Database Syst Rev. 2017 Nov 02;11:CD012847
pubmed: 29095502
Cancers (Basel). 2020 Apr 23;12(4):
pubmed: 32340164
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:73-85
pubmed: 28988647
Nucleic Acids Res. 1983 Aug 25;11(16):5747-61
pubmed: 6889135
Obstet Gynecol. 1984 Oct;64(4):451-8
pubmed: 6483293
Spectrochim Acta A Mol Biomol Spectrosc. 2017 Oct 5;185:317-335
pubmed: 28599236
Nature. 1958 May 31;181(4622):1531-2
pubmed: 13566051
JAMA. 2004 May 5;291(17):2100-6
pubmed: 15126438
Dtsch Med Wochenschr. 2012 Mar;137(9):419-24
pubmed: 22354796
J Biol Chem. 2003 Apr 25;278(17):14985-95
pubmed: 12576480
J Cell Physiol. 2002 Sep;192(3):327-38
pubmed: 12124778